Thus, longitudinal studies beginning at middle age or earlier will be critical for providing further clarity on the temporal trajectories of Aβ and tau accumulation and their associations with cognition in individuals who will and will not ultimately develop clinical AD. This evidence concerns the gene MAPT and Alzheimer disease.